Federated Hermes Inc. Cuts Stake in Humana Inc. (NYSE:HUM)

Federated Hermes Inc. trimmed its stake in Humana Inc. (NYSE:HUM - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,747 shares of the insurance provider's stock after selling 9,727 shares during the period. Federated Hermes Inc. owned about 0.13% of Humana worth $75,881,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Mariner LLC boosted its position in Humana by 2.3% in the 3rd quarter. Mariner LLC now owns 14,119 shares of the insurance provider's stock valued at $6,869,000 after buying an additional 312 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of Humana by 27.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 27,943 shares of the insurance provider's stock worth $13,595,000 after acquiring an additional 6,034 shares in the last quarter. Silverarc Capital Management LLC bought a new position in shares of Humana during the 3rd quarter worth approximately $4,865,000. Vest Financial LLC increased its stake in Humana by 43.3% during the 4th quarter. Vest Financial LLC now owns 27,993 shares of the insurance provider's stock valued at $12,815,000 after purchasing an additional 8,455 shares in the last quarter. Finally, Artemis Investment Management LLP increased its stake in Humana by 9.6% during the 4th quarter. Artemis Investment Management LLP now owns 64,573 shares of the insurance provider's stock valued at $29,563,000 after purchasing an additional 5,672 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE HUM traded up $3.50 during mid-day trading on Friday, reaching $328.33. The company's stock had a trading volume of 1,137,665 shares, compared to its average volume of 1,997,818. The stock has a 50-day moving average of $330.40 and a two-hundred day moving average of $400.99. The stock has a market capitalization of $39.61 billion, a P/E ratio of 16.57, a P/E/G ratio of 1.90 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.59 and a current ratio of 1.59. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Thursday, January 25th. The insurance provider reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.76 by ($0.87). Humana had a return on equity of 19.44% and a net margin of 2.34%. The firm had revenue of $26.46 billion for the quarter, compared to analyst estimates of $25.47 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. Humana's revenue for the quarter was up 17.9% on a year-over-year basis. On average, equities research analysts anticipate that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.08%. The ex-dividend date is Friday, June 28th. Humana's payout ratio is currently 17.86%.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita bought 545 shares of the stock in a transaction on Tuesday, February 20th. The stock was bought at an average price of $367.09 per share, with a total value of $200,064.05. Following the completion of the purchase, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.32% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. UBS Group restated a "neutral" rating and set a $370.00 price target (down previously from $530.00) on shares of Humana in a research note on Friday, January 26th. Truist Financial restated a "hold" rating and set a $550.00 price target on shares of Humana in a research note on Friday, January 19th. Mizuho dropped their price objective on shares of Humana from $550.00 to $400.00 and set a "buy" rating on the stock in a report on Friday, January 26th. TheStreet downgraded shares of Humana from a "b" rating to a "c+" rating in a report on Monday, January 8th. Finally, TD Cowen dropped their price objective on shares of Humana from $427.00 to $396.00 and set a "buy" rating on the stock in a report on Tuesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $465.42.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.